The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Dopamine turnover and glutathione oxidation: implications for Parkinson disease.
Open accessAbstract
Parkinson disease is characterized by a major loss (approximately 80% or more) of dopaminergic nigrostriatal neurons and by an increased turnover of neurotransmitter by surviving neurons of the nigrostriatal tract. In theory, increased turnover of dopamine should be associated with an oxidative stress derived from increased production of hydrogen peroxide. The peroxide is formed during the oxidative deamination of dopamine by monoamine oxidase. In experiments with mice, increased presynaptic turnover of dopamine was evoked by injection of reserpine, which interferes with the storage of dopamine in synaptic vesicles. Loss of dopamine and formation of deaminated metabolites were accompanied by a significant rise (87.8%) in the level of oxidized glutathione in brain. This change was observed in the striatum, which is richly innervated by dopamine terminals, but not in the frontal cortex, which receives a much sparser innervation by catecholamine nerve terminals. The rise in oxidized glutathione was seen even though dopamine terminals constitute only 1% or less of the mass of the striatum. Clorgyline, an inhibitor of monoamine oxidase type A, blocked the formation of oxidized glutathione. These observations confirm that a selective increase in neurotransmitter turnover within nigrostriatal nerve terminals can evoke a change in cellular redox status. We suggest that an oxidative stress may play a role in the natural history of Parkinson disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glowinski, J., & Iversen, L. L. (1966) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1966.tb09873.x · Cited by 5,406
The Biochemical Basis of Neuropharmacology.
(1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-81-4-575_2 · Cited by 1,878
Fuxé, K. (1965) · PubMed · Cited by 1,548
Oxygen metabolism and the toxic properties of phagocytes
KLEBANOFF, S. J. (1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-3-480 · Cited by 868
Biochemical pathophysiology of Parkinson's disease.
Hornykiewicz, O., & Kish, S. J. (1987) · PubMed · Cited by 849
Levitt, P., Pintar, J. E., & Breakefield, X. O. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.20.6385 · Cited by 526
Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization
Hefti, F., Melamed, E., & Wurtman, R. J. (1980) · Brain Research · doi:10.1016/0006-8993(80)90871-9 · Cited by 501
Adams, J. D., Lauterburg, B. H., & Mitchell, J. R. (1983) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22134-6 · Cited by 463
A Quantitative Study on the Nigro‐Neostriatal Dopamine Neuron System in the Rat
Andén, N., Fuxe, K., Hamberoer, B., & Hökfelt, T. (1966) · Acta Physiologica Scandinavica · doi:10.1111/j.1748-1716.1966.tb03317.x · Cited by 379
Gilbert, H. F. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)33682-2 · Cited by 262
Maker, H. S., Weiss, C., Silides, D. J., & Cohen, G. (1981) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1981.tb01631.x · Cited by 256
Self-citationThe pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence.
Cohen, G. (1983) · PubMed · Cited by 226
Self-citationOshino, N., & Chance, B. (1977) · Biochemical Journal · doi:10.1042/bj1620509 · Cited by 206
Reduced and oxidized glutathione in human and monkey brain
Slivka, A., Spina, M. B., & Cohen, G. (1987) · Neuroscience Letters · doi:10.1016/0304-3940(87)90061-9 · Cited by 162
Self-citationAltar, C. A., Marien, M. R., & Marshall, J. F. (1987) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1987.tb04106.x · Cited by 161
Cohen, G., Heikkila, R. E., Allis, B., Cabbat, F. S., Dembiec, D., MacNamee, D., Mytilineou, C., & Winston, B. (1976) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30688-9 · Cited by 113
Self-citationExposure of striatal [corrected] synaptosomes to L-dopa increases levels of oxidized glutathione.
Spina, M. B., & Cohen, G. (1988) · PubMed · Cited by 77
Self-citationKindt, M. V., Youngster, S. K., Sonsalla, P. K., Duvoisin, R. C., & Heikkila, R. E. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90308-1 · Cited by 42
Ponzio, F., Achilli, G., Calderini, G., et al. (1984) · Neurobiology of Aging · doi:10.1016/0197-4580(84)90038-1 · Cited by 39
Sutherland, M. W., Nelson, J., Harrison, G., & Forman, H. J. (1985) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(85)90509-0 · Cited by 35
Effects of different monoamine oxidase inhibitors on the metabolism of L-dopa in the rat brain
Buu, N. T., & Angers, M. (1987) · Biochemical Pharmacology · doi:10.1016/0006-2952(87)90060-8 · Cited by 32
Fuller, R. W., & Hemrick-Luecke, S. K. (1985) · Life Sciences · doi:10.1016/0024-3205(85)90352-2 · Cited by 31
Cited by
Halliwell, B. (2001) · Drugs & Aging · doi:10.2165/00002512-200118090-00004 · Cited by 1,502
Blum, D., Torch, S., Lambeng, N., Nissou, M.-F., Benabid, A.-L., Sadoul, R., & Verna, J.-M. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(01)00003-x · Cited by 1,246
Radical-free biology of oxidative stress
Jones, D. P. (2008) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00283.2008 · Cited by 1,213
Glutathione, oxidative stress and neurodegeneration
Schulz, J. B., Lindenau, J., Seyfried, J., & Dichgans, J. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01595.x · Cited by 1,213
The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it
Fahn, S., & Cohen, G. (1992) · Annals of Neurology · doi:10.1002/ana.410320616 · Cited by 927
Self-citation
Metadata
- Authors
- Spina, M. B., & Cohen, G.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1989-02
- Volume
- 86
- Issue
- 4
- Pages
- 1398-1400
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2054663416
- Cited by
- 395
- References
- 22
- FWCI
- 11.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.